International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting

Kathryn Lee; Michael J. Woodbury; Melissa Peri Zundell; Rosario Agüero; Jenna Yousif; Samuel Clay Williams; David Rosmarin; Nanette Silverberg; Diane Thiboutot; Cecilia Larocca; Michi M. Shinohara; Arash Mostaghimi; Sonja Ständer; Antonio Martorell; Tarannum Jaleel; Richard L. Torbeck; Daniel M. Siegel; Lourdes Perez-Chada; Vibeke Strand; April W. Armstrong; Joseph F. Merola; Alice B. Gottlieb

doi:10.36849/JDD.7615

International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting

Kathryn Lee, Michael J. Woodbury, Melissa Peri Zundell, Rosario Agüero, Jenna Yousif, Samuel Clay Williams, David Rosmarin, Nanette Silverberg, Diane Thiboutot, Cecilia Larocca, Michi M. Shinohara, Arash Mostaghimi, Sonja Ständer, Antonio Martorell, Tarannum Jaleel, Richard L. Torbeck, Daniel M. Siegel, Lourdes Perez-Chada, Vibeke Strand, April W. ArmstrongJoseph F. Merola, Alice B. Gottlieb

Research output: Contribution to journal › Article › peer-review

Abstract

Background: The International Dermatology Outcome Measures (IDEOM) is a non-profit organization dedicated to the advancement of evidence-based, consensus-driven outcome measures in dermatological diseases. Researchers and stakeholders from various backgrounds collaborate to develop these objective benchmark metrics to further advance treatment and management of dermatologic conditions. Summary: The 2022 IDEOM Annual Meeting was held on June 17-18, 2022. Leaders and stakeholders from the hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, cutaneous lymphoma, and psoriatic disease workgroups discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting.

Original language	English
Pages (from-to)	1153-1159
Number of pages	7
Journal	Journal of Drugs in Dermatology
Volume	22
Issue number	12
DOIs	https://doi.org/10.36849/JDD.7615
State	Published - Dec 2023

Access to Document

10.36849/JDD.7615

Cite this

Lee, K., Woodbury, M. J., Zundell, M. P., Agüero, R., Yousif, J., Williams, S. C., Rosmarin, D., Silverberg, N., Thiboutot, D., Larocca, C., Shinohara, M. M., Mostaghimi, A., Ständer, S., Martorell, A., Jaleel, T., Torbeck, R. L., Siegel, D. M., Perez-Chada, L., Strand, V., ... Gottlieb, A. B. (2023). International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting. Journal of Drugs in Dermatology, 22(12), 1153-1159. https://doi.org/10.36849/JDD.7615

@article{d6f6617d450746078899fcbd78725a55,

title = "International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting",

abstract = "Background: The International Dermatology Outcome Measures (IDEOM) is a non-profit organization dedicated to the advancement of evidence-based, consensus-driven outcome measures in dermatological diseases. Researchers and stakeholders from various backgrounds collaborate to develop these objective benchmark metrics to further advance treatment and management of dermatologic conditions. Summary: The 2022 IDEOM Annual Meeting was held on June 17-18, 2022. Leaders and stakeholders from the hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, cutaneous lymphoma, and psoriatic disease workgroups discussed the progress of their respective outcome-measures research. This report summarizes each workgroup{\textquoteright}s updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting.",

author = "Kathryn Lee and Woodbury, {Michael J.} and Zundell, {Melissa Peri} and Rosario Ag{\"u}ero and Jenna Yousif and Williams, {Samuel Clay} and David Rosmarin and Nanette Silverberg and Diane Thiboutot and Cecilia Larocca and Shinohara, {Michi M.} and Arash Mostaghimi and Sonja St{\"a}nder and Antonio Martorell and Tarannum Jaleel and Torbeck, {Richard L.} and Siegel, {Daniel M.} and Lourdes Perez-Chada and Vibeke Strand and Armstrong, {April W.} and Merola, {Joseph F.} and Gottlieb, {Alice B.}",

year = "2023",

month = dec,

doi = "10.36849/JDD.7615",

language = "English",

volume = "22",

pages = "1153--1159",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "12",

}

Lee, K, Woodbury, MJ, Zundell, MP, Agüero, R, Yousif, J, Williams, SC, Rosmarin, D, Silverberg, N, Thiboutot, D, Larocca, C, Shinohara, MM, Mostaghimi, A, Ständer, S, Martorell, A, Jaleel, T, Torbeck, RL, Siegel, DM, Perez-Chada, L, Strand, V, Armstrong, AW, Merola, JF & Gottlieb, AB 2023, 'International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting', Journal of Drugs in Dermatology, vol. 22, no. 12, pp. 1153-1159. https://doi.org/10.36849/JDD.7615

TY - JOUR

T1 - International Dermatology Outcome Measures (IDEOM)

T2 - Report From the 2022 Annual Meeting

AU - Lee, Kathryn

AU - Woodbury, Michael J.

AU - Zundell, Melissa Peri

AU - Agüero, Rosario

AU - Yousif, Jenna

AU - Williams, Samuel Clay

AU - Rosmarin, David

AU - Silverberg, Nanette

AU - Thiboutot, Diane

AU - Larocca, Cecilia

AU - Shinohara, Michi M.

AU - Mostaghimi, Arash

AU - Ständer, Sonja

AU - Martorell, Antonio

AU - Jaleel, Tarannum

AU - Torbeck, Richard L.

AU - Siegel, Daniel M.

AU - Perez-Chada, Lourdes

AU - Strand, Vibeke

AU - Armstrong, April W.

AU - Merola, Joseph F.

AU - Gottlieb, Alice B.

PY - 2023/12

Y1 - 2023/12

N2 - Background: The International Dermatology Outcome Measures (IDEOM) is a non-profit organization dedicated to the advancement of evidence-based, consensus-driven outcome measures in dermatological diseases. Researchers and stakeholders from various backgrounds collaborate to develop these objective benchmark metrics to further advance treatment and management of dermatologic conditions. Summary: The 2022 IDEOM Annual Meeting was held on June 17-18, 2022. Leaders and stakeholders from the hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, cutaneous lymphoma, and psoriatic disease workgroups discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting.

AB - Background: The International Dermatology Outcome Measures (IDEOM) is a non-profit organization dedicated to the advancement of evidence-based, consensus-driven outcome measures in dermatological diseases. Researchers and stakeholders from various backgrounds collaborate to develop these objective benchmark metrics to further advance treatment and management of dermatologic conditions. Summary: The 2022 IDEOM Annual Meeting was held on June 17-18, 2022. Leaders and stakeholders from the hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, cutaneous lymphoma, and psoriatic disease workgroups discussed the progress of their respective outcome-measures research. This report summarizes each workgroup’s updates from 2022 and their next steps as established during the 2022 IDEOM Annual Meeting.

UR - http://www.scopus.com/inward/record.url?scp=85178850409&partnerID=8YFLogxK

U2 - 10.36849/JDD.7615

DO - 10.36849/JDD.7615

M3 - Article

C2 - 38051841

AN - SCOPUS:85178850409

SN - 1545-9616

VL - 22

SP - 1153

EP - 1159

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

IS - 12

ER -

International Dermatology Outcome Measures (IDEOM): Report From the 2022 Annual Meeting

Abstract

Access to Document

Fingerprint

Cite this